Oliver Langer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4334247/publications.pdf

Version: 2024-02-01

157 papers	4,734 citations	81900 39 h-index	128289 60 g-index
159 all docs	159 docs citations	159 times ranked	4349 citing authors

#	Article	IF	Citations
1	Bloodâ€“brain barrier P-glycoprotein function in Alzheimer's disease. Brain, 2012, 135, 181-189.	7.6	252
2	P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurology, The, 2013, 12, 777-785.	10.2	155
3	Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nuclear Medicine and Biology, 2003, 30, 285-291.	0.6	123
4	Pharmacoresistance in Epilepsy: A Pilot PET Study with the P-Glycoprotein Substrate R -[11 C]verapamil. Epilepsia, 2007, 48, 1774-1784.	5.1	119
5	Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Bloodâ€“Brain Barrier: A Comparison With Rat Data. Clinical Pharmacology and Therapeutics, 2012, 91, 227-233.	4.7	108
6	Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 1183-1193.	1.0	105
7	Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Bloodâ€“Brain Barrier Studied with (R)-¹¹C-Verapamil and PET. Journal of Nuclear Medicine, 2008, 49, 1328-1335.	5.0	104
8	Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 942-953.	6.4	102
9	Approaches using molecular imaging technology â€" use of PET in clinical microdose studies. Advanced Drug Delivery Reviews, 2011, 63, 539-546.	13.7	102
10	A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Bloodâ€“Brain Barrier with (R)-¹¹C-Verapamil and PET. Journal of Nuclear Medicine, 2009, 50, 1954-1961.	5.0	99
11	Limitations of Small Animal PET Imaging with [18F]FDDNP and FDG for Quantitative Studies in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Molecular Imaging and Biology, 2009, 11, 236-240.	2.6	87
12	Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study. Drug Metabolism and Disposition, 2013, 41, 754-762.	3.3	79
13	In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 143-150.	6.4	77
14	Approaching Complete Inhibition of P-Glycoprotein at the Human Bloodâ€“Brain Barrier: An (R)-[¹¹C]Verapamil PET Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 743-746.	4.3	74
15	Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorganic and Medicinal Chemistry, 2010, 18, 5489-5497.	3.0	73
16	Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Bloodâ˜'Brain Barrier. Journal of Medicinal Chemistry, 2009, 52, 6073-6082.	6.4	71
17	Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS Journal, 2006, 8, E263-E271.	4.4	70
18	Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs. Current Drug Metabolism, 2004, 5, 463-481.	1.2	70

#	Article	IF	Citations
19	(R)-[11C]verapamil is selectively transported by murine and human P-glycoprotein at the bloodâ€“brain barrier, and not by MRP1 and BCRP. Nuclear Medicine and Biology, 2013, 40, 873-878.	0.6	67
20	PET and SPET tracers for mapping the cardiac nervous system. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 416-434.	6.4	66
21	Alzheimerâ€™s and ABC transporters â€" new opportunities for diagnostics and treatment. Neurobiology of Disease, 2014, 72, 54-60.	4.4	66
22	Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. European Journal of Clinical Pharmacology, 2009, 65, 941-946.	1.9	65
23	Influence of functional haplotypes in the drug transporter gene on central nervous system drug distribution in humans. Clinical Pharmacology and Therapeutics, 2005, 78, 182-190.	4.7	64
24	PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo. Current Drug Metabolism, 2011, 12, 774-792.	1.2	59
25	PET-MR and SPECT-MR multimodality probes: Development and challenges. Theranostics, 2018, 8, 6210-6232.	10.0	59
26	A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood-Brain Barrier. Journal of Neuroscience, 2011, 31, 8803-8811.	3.6	58
27	Imaging techniques to study drug transporter function in vivo. , 2018, 189, 104-122.		57
28	Phase 0/microdosing approaches: time for mainstream application in drug development?. Nature Reviews Drug Discovery, 2020, 19, 801-818.	46.4	55
29	[18 F]Ciprofloxacin, a New Positron Emission Tomography Tracer for Noninvasive Assessment of the Tissue Distribution and Pharmacokinetics of Ciprofloxacin in Humans. Antimicrobial Agents and Chemotherapy, 2004, 48, 3850-3857.	3.2	54
30	A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimerâ€™s disease. Clinical Pharmacology and Therapeutics, 2006, 80, 216-227.	4.7	53
31	Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of ¹¹C-Erlotinib. Journal of Nuclear Medicine, 2015, 56, 1930-1936.	5.0	52
32	Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Bloodâ€“Brain Barrier. Clinical Pharmacology and Therapeutics, 2016, 100, 131-141.	4.7	50
33	Improved specific radioactivity of the PET radioligand [11C]FLB 457 by use of the GE medical systems PETtrace MeI microlab. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 331-338.	1.0	49
34	Use of PET Imaging to Evaluate Transporterâ€Mediated Drugâ€Drug Interactions. Journal of Clinical Pharmacology, 2016, 56, S143-56.	2.0	48
35	A Novel PET Protocol for Visualization of Breast Cancer Resistance Protein Function at the Bloodâ€“Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 2002-2011.	4.3	46
36	Interaction of ¹¹C-Tariquidar and ¹¹C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Bloodâ€“Brain Barrier. Journal of Nuclear Medicine, 2013, 54, 1181-1187.	5.0	45

#	Article	IF	Citations
37	Radioligands targeting Pâ€glycoprotein and other drug efflux proteins at the bloodâ€“brain barrier. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 68-77.	1.0	45
38	Biological evaluation of 2â€²-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nuclear Medicine and Biology, 2004, 31, 291-295.	0.6	43
39	Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Bloodâ€“Brain Barrier: A PET Study on Nonhuman Primates. Journal of Nuclear Medicine, 2017, 58, 117-122.	5.0	43
40	Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology and Therapeutics, 2018, 104, 139-147.	4.7	43
41	Microdosing Studies in Humans. Drugs in R and D, 2008, 9, 73-81.	2.2	42
42	Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model. Scientific Reports, 2019, 9, 16310.	3.3	42
43	Synthesis of high-specific-radioactivity 4- and 6-[18F]fluorometaraminol- PET tracers for the adrenergic nervous system of the heart. Bioorganic and Medicinal Chemistry, 2001, 9, 677-694.	3.0	40
44	Imaging of P-glycoprotein Function and Expression to Elucidate Mechanisms of Pharmacoresistance in Epilepsy. Current Topics in Medicinal Chemistry, 2010, 10, 1785-1791.	2.1	40
45	Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 116-123.	6.4	39
46	Factors Governing P-Glycoprotein-Mediated Drugâ€“Drug Interactions at the Bloodâ€“Brain Barrier Measured with Positron Emission Tomography. Molecular Pharmaceutics, 2015, 12, 3214-3225.	4.6	39
47	P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of ¹¹C-Metoclopramide Across the Bloodâ€“Brain Barrier: A PET Study on Nonhuman Primates. Journal of Nuclear Medicine, 2018, 59, 1609-1615.	5.0	39
48	Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate ¹¹C-Metoclopramide Assessed with PET Imaging in Humans. Journal of Nuclear Medicine, 2019, 60, 985-991.	5.0	38
49	In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 2014, 83, 1326-1331.	1.1	37
50	Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. Journal of Nuclear Medicine, 2005, 46, 1835-41.	5.0	35
51	Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Bloodâ€“Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 510-515.	4.3	34
52	Gastric Cancer Growth Control by BEZ235In VivoDoes Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake. Clinical Cancer Research, 2011, 17, 5322-5332.	7.0	33
53	Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, 611C9RGH-1756 in the monkey brain. Neurochemistry International, 2004, 45, 609-617.	3.8	31
54	A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil. Clinical Pharmacokinetics, 2011, 50, 111-120.	3.5	31

#	Article	IF	Citations
55	Using Positron Emission Tomography to Study Transporter-Mediated Drugâ€“Drug Interactions in Tissues. Clinical Pharmacology and Therapeutics, 2014, 96, 206-213.	4.7	31
56	Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. Bioorganic and Medicinal Chemistry, 2011, 19, 2190-2198.	3.0	30
57	Effect of Pâ€glycoprotein inhibition at the bloodâ€“brain barrier on brain distribution of (R)â€[¹¹C]verapamil in elderly vs. young subjects. British Journal of Clinical Pharmacology, 2017, 83, 1991-1999.	2.4	28
58	New ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis, 2009, 1, 357-366.	1.5	27
59	Imaging Pâ€Glycoprotein Function at the Bloodâ€“Brain Barrier as a Determinant of the Variability in Response to Central Nervous System Drugs. Clinical Pharmacology and Therapeutics, 2019, 105, 1061-1064.	4.7	25
60	A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Bloodâ€“Brain Barrier. Journal of Nuclear Medicine, 2019, 60, 486-491.	5.0	25
61	Carbon-11 pb-12: an attempt to visualize the dopamine d4 receptor in the primate brain with positron emission tomography. Nuclear Medicine and Biology, 2000, 27, 707-714.	0.6	24
62	EGFR is required for FOSâ€dependent bone tumor development via RSK2/CREB signaling. EMBO Molecular Medicine, 2018, 10, .	6.9	24
63	A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 149-159.	6.4	23
64	Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model. Molecular Pharmacology, 2016, 89, 492-504.	2.3	23
65	Assessment of P-Glycoprotein Transport Activity at the Human Bloodâ€“Retina Barrier with (R)â€¹¹C-Verapamil PET. Journal of Nuclear Medicine, 2017, 58, 678-681.	5.0	23
66	Development and performance test of an online blood sampling system for determination of the arterial input function in rats. EJNMMI Physics, 2015, 2, 1.	2.7	22
67	A novel electrophilic synthesis and evaluation of medium specific radioactivity (1R,2S)-4-[18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PET. Nuclear Medicine and Biology, 2004, 31, 103-110.	0.6	21
68	Expression of endogenous mouse APP modulates Î²-amyloid deposition in hAPP-transgenic mice. Acta Neuropathologica Communications, 2017, 5, 49.	5.2	21
69	Imaging P-Glycoprotein Induction at the Bloodâ€“Brain Barrier of a Î²-Amyloidosis Mouse Model with ¹¹C-Metoclopramide PET. Journal of Nuclear Medicine, 2020, 61, 1050-1057.	5.0	21
70	Absolute quantitation of iodine-123 epidepride kinetics using single-photon emission tomography: comparison with carbon-11 epidepride and positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1580-1588.	6.4	20
71	Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors. Nuclear Medicine and Biology, 1999, 26, 509-518.	0.6	20
72	Inhibition of ABCB1 and ABCG2 at the Mouse Bloodâ€“Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [¹¹C]erlotinib. Molecular Pharmaceutics, 2019, 16, 1282-1293.	4.6	20

#	Article	IF	Citations
73	Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 150-162.	4.3	20
74	Preparation of [18F]Î²-CFT-FP and [11C]Î²-CFT-FP, selective radioligands for visualisation of the dopamine transporter using positron emission tomography (PET). Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 1235-1244.	1.0	19
75	Radiosynthesis and Assessment of Ocular Pharmacokinetics of 124I-Labeled Chitosan in Rabbits Using Small-Animal PET. Molecular Imaging and Biology, 2011, 13, 222-226.	2.6	19
76	Preparation of 4-[11C]methylmetaraminol, a potential PET tracer for assessment of myocardial sympathetic innervation. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 55-65.	1.0	18
77	Factors That Limit Positron Emission Tomography Imaging of P-Glycoprotein Density at the Bloodâ€“Brain Barrier. Molecular Pharmaceutics, 2013, 10, 2222-2229.	4.6	18
78	Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography. Journal of Medicinal Chemistry, 2015, 58, 6058-6080.	6.4	18
79	Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 599-606.	1.6	18
80	High specific radioactivity (1R,2S)-4-[18F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart. Nuclear Medicine and Biology, 2000, 27, 233-238.	0.6	17
81	Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [11C]MC113. Nuclear Medicine and Biology, 2012, 39, 1219-1225.	0.6	17
82	Effect of Rifampicin on the Distribution of [¹¹C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Molecular Pharmaceutics, 2018, 15, 4589-4598.	4.6	17
83	Complete inhibition of ABCB1 and ABCG2 at the bloodâ€“brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹C]erlotinib. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1634-1646.	4.3	17
84	Use of imaging to assess the activity of hepatic transporters. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 149-164.	3.3	17
85	Pharmacokinetic modeling of P-glycoprotein function at the rat and human bloodâ€“brain barriers studied with (R)-[11C]verapamil positron emission tomography. EJNMMI Research, 2012, 2, 58.	2.5	16
86	Assessing the Activity of Multidrug Resistanceâ€“Associated Protein 1 at the Lung Epithelial Barrier. Journal of Nuclear Medicine, 2020, 61, 1650-1657.	5.0	16
87	Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. Nuclear Medicine and Biology, 2013, 40, 755-763.	0.6	15
88	Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[11C]Methylpurine in Mice. Molecular Imaging and Biology, 2019, 21, 306-316.	2.6	15
89	Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [11C]Tariquidar and PET in Humans and Mice. Molecular Pharmaceutics, 2020, 17, 316-326.	4.6	15
90	On the applicability of [18F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy. Nuclear Medicine and Biology, 2017, 44, 83-89.	0.6	14

#	Article	IF	Citations
91	Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. AAPS Journal, 2019, 21, 61.	4.4	14
92	Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 954-965.	4.3	14
93	Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 175-185.	4.3	14
94	Synthesis of fluorine-18-labelled 5- and 6-fluoro-2-pyridinamine. Journal of Labelled Compounds and Radiopharmaceuticals, 2006, 49, 345-356.	1.0	13
95	Synthesis and preclinical characterization of 1-(6â€²-deoxy-6â€²-[18 F]fluoro-Î²- d) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 587 T assess tumor hypoxia. Bioorganic and Medicinal Chemistry, 2016, 24, 5326-5339.	3.0	13
96	Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology and Therapeutics, 2021, 109, 754-761.	4.7	13
97	Synthesis of 1,1â€² [11C]-methylene-di-(2-naphthol) ([11C]ST1859) for PET studies in humans. Journal of Labelled Compounds and Radiopharmaceuticals, 2005, 48, 577-587.	1.0	12
98	Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nuclear Medicine and Biology, 2010, 37, 637-644.	1.6	12
99	The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the bloodâ€“brain barrier: A positron emission tomography study. Epilepsy Research, 2012, 100, 93-103.	1.6	12
100	Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines. Applied Radiation and Isotopes, 2016, 118, 67-72.	1.5	12
101	Tobacco Smoke and Inhaled Drugs Alter Expression and Activity of Multidrug Resistance-Associated Protein-1 (MRP1) in Human Distal Lung Epithelial Cells in vitro. Frontiers in Bioengineering and Biotechnology, 2020, 8, 1030.	4.1	12
102	Positron emission tomography for use in microdosing studies. Current Opinion in Drug Discovery & Development, 2008, 11, 104-10.	1.9	12
103	Role of (Drug) Transporters in Imaging in Health and Disease. Drug Metabolism and Disposition, 2014, 42, 2007-2015.	3.3	11
104	Whole-Body Distribution and Radiation Dosimetry of ¹¹C-Elacridar and ¹¹C-Tariquidar in Humans. Journal of Nuclear Medicine, 2016, 57, 1265-1268.	5.0	11
105	Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by [11C]erlotinib and Positron Emission Tomography. Drug Metabolism and Disposition, 2017, 45, 1093-1100.	3.3	11
106	PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats. Journal of Controlled Release, 2022, 342, 44-52.	9.9	11
107	Radiochemical labelling of the dopamine D3 receptor ligand RGH-1756. Journal of Labelled Compounds and Radiopharmaceuticals, 2000, 43, 1069-1074.	1.0	10
108	A general method for the fluorine-18 labelling of fluoroquinolone antibiotics. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 715-727.	1.0	10

#	Article	IF	Citations
109	Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 8.	3.9	10
110	Interaction of HM30181 with P-glycoprotein at the murine bloodâ€“brain barrier assessed with positron emission tomography. European Journal of Pharmacology, 2012, 696, 18-27.	3.5	9
111	Automated electrophilic radiosynthesis of [18F]FBPA using a modified nucleophilic GE TRACERlab FXFDG. Applied Radiation and Isotopes, 2015, 104, 124-127.	1.5	9
112	Preparation of 4- and 6-[76Br] bromometaraminol, two potential radiotracers for the study of the myocardial norepinephrine neuronal reuptake system with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 1997, 39, 803-816.	1.0	8
113	Comparison of three different purification methods for the routine preparation of [11C] Metomidate. Applied Radiation and Isotopes, 2003, 59, 125-128.	1.5	8
114	Reproducibility of Quantitative Brain Imaging Using a PET-Only and a Combined PET/MR System. Frontiers in Neuroscience, 2017, 11, 396.	2.8	8
115	Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats. EJNMMI Research, 2018, 8, 81.	2.5	8
116	Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. Drug Delivery and Translational Research, 2018, 8, 536-542.	5.8	7
117	PET imaging of the mouse brain reveals a dynamic regulation of SERT density in a chronic stress model. Translational Psychiatry, 2019, 9, 80.	4.8	7
118	Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats. Pharmaceutics, 2020, 12, 486.	4.5	7
119	Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice. Pharmaceutics, 2021, 13, 1286.	4.5	7
120	Influence of ABC transporters on the excretion of ciprofloxacin assessed with PET imaging in mice. European Journal of Pharmaceutical Sciences, 2021, 163, 105854.	4.0	7
121	Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramide. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 31.	3.9	7
122	ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure. Frontiers in Pharmacology, 2021, 12, 698966.	3.5	6
123	[11 C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. Nuclear Medicine and Biology, 2017, 52, 7-15.	0.6	6
124	Strategic, feasibility, economic, and cultural aspects of phase 0 approaches. Clinical and Translational Science, 2022, 15, 1355-1379.	3.1	6
125	[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 741-749.	6.4	5
126	Automated radiosynthesis of [18F]ciprofloxacin. Applied Radiation and Isotopes, 2015, 99, 133-137.	1.5	5

#	Article	IF	Citations
127	Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [18F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. Journal of Pharmaceutical Sciences, 2016, 105, 106-112.	3.3	5
128	PET probes for imaging pancreatic islet cells. Clinical and Translational Imaging, 2017, 5, 507-523.	2.1	5
129	Microdialysis Versus Other Techniques for the Clinical Assessment of In Vivo Tissue Drug Distribution. AAPS Journal, 2006, 08, E263.	4.4	5
130	Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. Clinical Pharmacokinetics, 2022, , 1.	3.5	5
131	Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats. Journal of Controlled Release, 2022, 349, 109-117.	9.9	5
132	Some new methods for the synthesis of cardiac neurotransmission PET radiotracers. Nuclear Medicine and Biology, 1995, 22, 1037-1043.	0.6	4
133	A Prediction Method for P-glycoproteinâ€“Mediated Drugâ€“Drug Interactions at the Human Bloodâ€“Brain Barrier From Blood Concentrationâ€“Time Profiles, Validated With PET Data. Journal of Pharmaceutical Sciences, 2017, 106, 2780-2786.	3.3	4
134	Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. European Journal of Pharmaceutical Sciences, 2018, 115, 212-222.	4.0	4
135	Molar activity â€“ The keystone in 11C-radiochemistry: An explorative study using the gas phase method. Nuclear Medicine and Biology, 2018, 67, 21-26.	0.6	4
136	Generation and Characterization of anAbcc1Humanized Mouse Model (hABCC1^{flx/flx}) with Knockout Capability. Molecular Pharmacology, 2019, 96, 138-147.	2.3	4
137	Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model. International Journal of Molecular Sciences, 2020, 21, 8245.	4.1	4
138	Repurposing 99mTc-Mebrofenin as a Probe for Molecular Imaging of Hepatocyte Transporters. Journal of Nuclear Medicine, 2021, 62, 1043-1047.	5.0	4
139	Evaluation of [11C]elacridar and [11C]tariquidar in transporter knockout mice using small-animal PET. NeuroImage, 2010, 52, S25.	4.2	3
140	In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2026-2035.	6.4	3
141	[18F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent bloodâ€“brain barrier. Nuclear Medicine and Biology, 2015, 42, 585-589.	0.6	2
142	Humanization of the bloodâ€“brain barrier transporter ABCB1 in mice disrupts genomic locus â€” lessons from three unsuccessful approaches. European Journal of Microbiology and Immunology, 2018, 8, 78-86.	2.8	2
143	Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates. Pharmaceutics, 2021, 13, 918.	4.5	2
144	Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. EJNMMI Research, 2019, 9, 110.	2.5	2

#	Article	IF	Citations
145	Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats. Pharmaceuticals, 2022, 15, 392.	3.8	2
146	Use of PET Imaging to Assess the Efficacy of Thiethylperazine to Stimulate Cerebral MRP1 Transport Activity in Wild-Type and APP/PS1-21 Mice. International Journal of Molecular Sciences, 2022, 23, 6514.	4.1	2
147	Liver Imaging and Hepatobiliary Contrast Media. Contrast Media and Molecular Imaging, 2018, 2018, 1-2.	0.8	1
148	Influence of Cation Transporters (OCTs and MATEs) on the Renal and Hepatobiliary Disposition of [11C]Metoclopramide in Mice. Pharmaceutical Research, 2021, 38, 127-140.	3.5	1
149	Tools in Clinical Pharmacology: Imaging Techniques. , 2016, , 139-150.		1
150	Small-animal PET evaluation of [11C]MC113 as a PET tracer for P-glycoprotein. BMC Pharmacology, 2010, 10, .	0.4	0
151	Dose-response assessment of tariquidar for inhibition of P-glycoprotein at the human blood-brain barrier using (R)-[11C]verapamil PET. BMC Pharmacology, 2010, 10, .	0.4	0
152	Complementary Techniques: Positron Emission Tomography. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 269-282.	0.6	0
153	32nd International Austrian Winter Symposium. EJNMMI Research, 2016, 6, 32.	2.5	0
154	Pharmacokinetic Imaging with Radiolabeled Molecularly Targeted Anticancer Drugs. Journal of Nuclear Medicine, 2020, 61, 306-306.	5.0	0
155	Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 2021, 23, 180-185.	2.6	0
156	Tools in clinical pharmacology - imaging techniques. , 2010, , 193-203.		0
157	Investigation of Transporter-Mediated Drug-Drug Interactions Using PET/MRI. , 2019, , 117-133.		0